Flumazenil Antagonism of Remimazolam in Kidney Transplant Patients

Launched by QIANFOSHAN HOSPITAL · Jul 30, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how a drug called flumazenil can influence the effects of another drug, remimazolam, in patients who are having kidney transplant surgery. The goal is to see how different doses of flumazenil affect the levels of remimazolam in the bloodstream during surgery, which is performed under general anesthesia. This research aims to improve anesthesia management for kidney transplant patients.

To participate in this trial, you need to be an adult between 18 and 65 years old and scheduled for an elective kidney transplant. You must also be able to give your consent to join the study. However, if you have certain health issues, like liver problems or a history of serious allergic reactions to narcotics, you won't be eligible. If you decide to join, you can expect to receive the study drugs during your surgery and be monitored closely by the medical team. It’s important to know that this trial is not yet recruiting participants, so it may take some time before it starts.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥ 18 years and \< 65 years
• • Patients undergoing elective kidney transplant surgery
• • Signed the informed consent for the clinical study
• Exclusion Criteria:
• • Liver decompensation (Child B/C)
• • History of liver transplant
• • Previous allergies or other serious adverse reactions to narcotic drugs
• • Intraoperative depth monitoring of anesthesia is not expected
• • Preoperative ASA rating of 5
• • Received general anesthesia in the 30 days prior to surgery or plan to receive it again within 30 days
• • Plan to extend airway protection or mechanical ventilation support time after surgery
• • Previous participation in this study